Daniel A. Ermann MD

Daniel Ermann, MD, joined the Division of Hematology/Hematologic Malignancies as an Associate Professor in 2023 after completing his Hematology/Oncology fellowship at the Huntsman Cancer Institute of the University of Utah. Dr. Ermann’s clinical expertise is focused on patients with chronic lymphocytic leukemia (CLL) and other forms of non-Hodgkin lymphoma (NHL). He is passionate about working towards a cure for these malignancies. Dr. Ermann is currently the physician lead of the CLL clinical trials program at Huntsman Cancer Institute.

His primary research interests include: implementing new targeted therapies for patients with CLL and lymphoma, evaluating novel treatment combinations, and developing supportive clinical trials for the complications of CLL. Dr. Ermann's research focus is to develop and implement ground-breaking clinical trials that can lead to new standards of care/treatments for CLL and NHL patients. Dr. Ermann is the principal investigator on more than 8 ongoing clinical trials at Huntsman Cancer Institute and is involved in the national SWOG CLL Working Group, which develops and opens important trials for CLL patients around the world.

He is also focused on evaluating and improving the outcomes and research, on current standards of care across the spectrum of lymphoma management. Dr. Ermann is originally from Pennsylvania, where he graduated from the University of Pittsburgh. He earned his medical degree from St. George’s University prior to completing his Internal Medicine residency training at Creighton University in Omaha, Nebraska.